The aim of this study (ARTEMIS study) was to investigate whether ziltivekimab could be used to treat patients admitted to hospital with acute myocardial infarction.

Start Date08 Oct 2024

Sponsor / Collaborator

Novo Nordisk China Pharmaceuticals Co. Ltd.

[+2]

CTRI/2024/06/068283 / RecruitingPhase 3

Effects of ziltivekimab versus placebo on cardiovascular outcomes inpatients with acute myocardial infarction - ARTEMIS

Start Date25 Jun 2024

Sponsor / Collaborator

Novo Nordisk A/S

NCT06118281 / RecruitingPhase 3

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

Start Date25 Jun 2024

Sponsor / Collaborator

Novo Nordisk A/S

[+1]

100 Clinical Results associated with Ziltivekimab

100 Translational Medicine associated with Ziltivekimab

100 Patents (Medical) associated with Ziltivekimab

Literatures (Medical) associated with Ziltivekimab

01 Jan 2024·Journal of the American Society of Nephrology : JASN

Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE)

Article

Author: Pergola, Pablo E ; Davidson, Michael ; Andreas Schytz, Philip ; Perkovic, Vlado ; Mohseni Zonoozi, Amir A ; Raj, Dominic S ; Jensen, Camilla ; Tuttle, Katherine R

Significance Statement:

Systemic inflammation in CKD can lead to anemia. Ziltivekimab, a fully human monoclonal antibody targeting the IL-6 ligand, has been shown to reduce systemic inflammation in patients with CKD. It has also been shown to increase serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to treatment with erythropoiesis-stimulating agents. This exploratory analysis of the RESCUE clinical trial found that among patients with CKD stage 3–5 and systemic inflammation, ziltivekimab treatment significantly increased hemoglobin (Hb) levels after 12 weeks compared with placebo. Ziltivekimab was also associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation. No major safety concerns were reported. Further clinical trials are warranted to study ziltivekimab's potential for anemia management in patients with CKD.

Background:

In the phase 2 RESCUE clinical trial, ziltivekimab, a fully human monoclonal antibody against the IL-6 ligand, significantly reduced the biomarkers of inflammation compared with placebo, in patients with CKD and systemic inflammation (high-sensitivity C-reactive protein ≥2 mg/L). The aim of this subanalysis of RESCUE trial data was to assess the effect of ziltivekimab on Hb and iron homeostasis in this patient population.

Methods:

This was an analysis of exploratory end points from the RESCUE trial (NCT03926117), which included 264 adults with CKD stage 3–5 and high-sensitivity C-reactive protein ≥2 mg/L. Participants received placebo or subcutaneous ziltivekimab (7.5, 15, or 30 mg) (1:1:1:1) once every 4 weeks, up to 24 weeks. End points for this analysis were changes in Hb and biomarkers of iron homeostasis from baseline to week 12.

Results:

The trial was terminated early due to the coronavirus disease 2019 pandemic, and thus, data up to week 12 are presented. Hb levels significantly increased from baseline to week 12 with ziltivekimab 7.5, 15, and 30 mg (treatment differences versus placebo: +0.57 g/dl [95% confidence interval, 0.27 to 0.86], +1.05 g/dl [0.76 to 1.33], and +0.99 g/dl [0.70 to 1.28], respectively, all P < 0.001). Ziltivekimab was associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation from baseline to week 12 (P < 0.05 versus placebo for all doses and comparisons). Cases of sustained thrombocytopenia, sustained neutropenia, anemia, and iron deficiency anemia were infrequent and similar across all groups.

Conclusions:

Anti-inflammatory therapy with ziltivekimab improved the markers of anemia and iron homeostasis in people with stage 3–5 CKD and systemic inflammation, suggesting a possible role in anemia management.

01 Oct 2023·Journal of cardiology

Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial.

Article

Author: Wada, Yukihiro ; Honda, Hirokazu ; Meyer, Anna Sina Pettersson ; Zonoozi, Amir Abbas Mohseni ; Jensen, Camilla

BACKGROUND:

Despite optimal treatment, a residual inflammatory risk often remains in patients with atherosclerotic cardiovascular disease. In a US-based phase 2 trial, ziltivekimab, a fully human monoclonal antibody targeting the interleukin-6 ligand, significantly reduced biomarkers of inflammation compared with placebo in patients at high atherosclerotic risk. Here, we report the efficacy and safety of ziltivekimab in Japanese patients.

METHODS:

RESCUE-2 was a randomized, double-blind, 12-week, phase 2 trial. Participants aged ≥20 years with stage 3-5 non-dialysis-dependent chronic kidney disease and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L were randomized to receive placebo (n = 13) or subcutaneous ziltivekimab 15 mg (n = 11) or 30 mg (n = 12) at Weeks 0, 4, and 8. The primary endpoint was percentage change in hsCRP levels from baseline to end of treatment (EOT; mean of Week 10 and Week 12 values).

RESULTS:

At EOT, median hsCRP levels were reduced by 96.2 % in the 15 mg group (p < 0.0001 versus placebo), by 93.4 % in the 30 mg group (p = 0.002 versus placebo), and by 27.0 % in the placebo group. Serum amyloid A and fibrinogen levels were also reduced significantly. Ziltivekimab was well tolerated and did not affect total cholesterol to high-density lipoprotein cholesterol ratios. There was a small, but statistically significant increase in triglyceride levels with ziltivekimab 15 mg and 30 mg compared with placebo.

CONCLUSIONS:

The efficacy and safety results support the development of ziltivekimab for secondary prevention and the treatment of patients at high atherosclerotic risk.

CLINICALTRIALS:

gov identifier, NCT04626505.

News (Medical) associated with Ziltivekimab

25 Mar 2024

·www.fiercebiotech.com

Novo Nordisk inks $1B Cardior buyout to pump up heart failure plans

Novo Nordisk moved to buy Cardior Pharmaceuticals after identifying CDR132L as a molecule with “a distinctive mode of action.” Novo Nordisk is pumping up its heart failure plans. The drugmaker, swelled by its GLP-1 windfall, has decided to buy Cardior Pharmaceuticals and its midphase prospect in a deal that could top out above 1 billion euros ($1.1 billion). Cardior is developing an antisense oligonucleotide to inhibit a piece of non-coding RNA, miR-132, that is implicated in heart failure. Upregulation of the RNA when certain cells are stressed can lead to changes in the size and shape of the heart. Blocking elevated miR-132 could therefore prevent or reverse changes that are associated with poor prognosis in patients who have heart attacks. The biotech raised 64 million euros from investors including Bristol Myers Squibb in 2021 and used the cash to take (PDF) its oligonucleotide, CDR132L, into a phase 2 trial the next year. Cardior has designed the 280-subject study to show CDR132L’s effect on the volume of blood in part of the heart. Cardior is still months away from the primary completion of the study, according to ClinicalTrials.gov, but Novo Nordisk is already planning to expand development. The Danish drugmaker plans to run another phase 2 trial in chronic heart failure patients with cardiac hypertrophy, a condition that negatively affects the heart’s ability to pump blood. CDR132L will slot into a pipeline that already features heart failure programs. Novo Nordisk reported clinical trial data on semaglutide, the active ingredient in Ozempic and Wegovy, in heart failure patients last year. The company is running a phase 3 trial of the IL-6 inhibitor ziltivekimab in a heart failure patient population and is working with Heartseed to test a cell therapy in an early-phase study. Novo Nordisk moved to buy Cardior after identifying CDR132L as a molecule with “a distinctive mode of action” that has the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people living with heart failure.” Advances in the treatment of heart failure have so far largely focused on managing the symptoms. CDR132L could address the underlying causes. The potential for CDR132L to provide long-lasting improvement in heart function led Novo Nordisk to put together an offer worth up to 1.025 billion euros for Cardior. The package includes an upfront payment and milestones, but neither party has provided a breakdown of the deal.

Phase 2OligonucleotidePhase 3Cell Therapy

05 May 2023

·www.prnewswire.com

Chronic Kidney Disease Competitive Landscape Report 2023: Comprehensive Insights About 75+ Companies and 95+ Drugs

DUBLIN, May 5, 2023 /PRNewswire/ -- The "Chronic Kidney Disease - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 95+ drugs in Chronic Kidney Disease Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in a Phase 2 clinical program for ADPKD. In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio. In January 2023, The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced. In November 2022, The Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company, announced that EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P< 0.0001). In October 2022, Revelation Biosciences Inc. announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner in the medium and high dose groups (21.7% reduction (p < 0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)). In October 2022, French Biopharma Company, Poxel SA announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator - and is also a phase 2 ready ADPKD asset, subject to additional financing. In-depth Commercial Assessment: Chronic Kidney Disease Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Current Treatment Scenario and Emerging Therapies: How many companies are developing Chronic Kidney Disease drugs? How many Chronic Kidney Disease drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Chronic Kidney Disease and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players Boehringer Ingelheim Eli Lilly and Company Reata Pharmaceuticals Novo Nordisk KBP Biosciences AstraZeneca Allena Pharmaceuticals SCOHIA PHARMA DiaMedica Therapeutics CinCor Pharma Galapagos NV Sentien Biotechnologies, Inc. Regeneron Pharmaceuticals UnicoCell Biomed OccuRx Pharmicell Lisata Therapeutics Unicycive Therapeutics Senda Biosciences Sarfez Pharmaceuticals Rege Nephro Orgenesis GNI Group Algomedix Maze Therapeutics Chinook Therapeutics Angion Biomedica Corp Arch Biopartners Scohia Pharma Algernon Pharmaceuticals TICEBA GmbH Key Products Empagliflozin Bardoxolone methyl Ziltivekimab KBP-5074 AZD9977 ALLN-346 BI-685509 SCO-792 DM199 Baxdrostat GLPG2737 SBI-101 REGN5459 ELIXCYTE FT011 Cellgram-CKD CLBS201 UNI-494 Research Program SZ007 Renal progenitor cells MSCKD F351 Research programme: TRPC6 antagonist APOL1 Programme Research and discovery programs: severe chronic kidney disease ROCK2 Inhibitor LSALT peptide SCO-116 Repirinast Polycystic kidney disease (PKD) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Clinical ResultAcquisitionPhase 2Phase 3Orphan Drug

27 Apr 2023

·www.prnewswire.com

Chronic Kidney Disease Market to Observe Impressive Growth at a CAGR of 8.7% by 2032, Estimates DelveInsight

The expected launch of therapies by several pharma companies such as ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, AstraZeneca, and others will lead to change in the chronic kidney disease market dynamic during the forecast period (2023-2032) LAS VEGAS, April 27, 2023 /PRNewswire/ -- DelveInsight's Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic kidney disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Chronic Kidney Disease Market Report As per DelveInsight analysis, the chronic kidney disease market size in the 7MM was approximately USD 5 billion in 2022. According to the assessment done by DelveInsight, the estimated total diagnosed prevalent chronic kidney disease cases in the 7MM were approximately 16 million in 2022. Leading chronic kidney disease companies such as ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, and others are developing novel chronic kidney disease drugs that can be available in the chronic kidney disease market in the coming years. The promising chronic kidney disease therapies in the pipeline include Renal Autologous Cell Therapy (REACT), Bardoxolone methyl, Ziltivekimab, Semaglutide, JARDIANCE (empagliflozin), KBP-5074, KT-301, CIN-107 (Baxdrostat), Zibotentan, ALLN-346, DM199, Sotagliflozin , and others. Discover which therapies are expected to grab the major chronic kidney disease market share @ Chronic Kidney Disease Market Report Chronic Kidney Disease Overview Chronic kidney disease occurs when the kidneys get damaged and cannot filter blood as efficiently as they should. Chronic kidney disease is defined as abnormalities in kidney structure or function that have been present for more than three months and have a negative impact on health. Chronic kidney disease is categorized into five phases based on the extent of kidney damage and function. In stage 1, there is modest kidney disease, and in stage 5, the kidneys have stopped working. The severity of chronic kidney disease varies. In the early stages of kidney disease, there are usually no chronic kidney disease symptoms. It can only be diagnosed if a blood or urine test is performed for another reason and the results show a kidney issue. Tiredness, swollen ankles, feet, or hands, shortness of breath, unwellness, and blood in the urine indicate a more advanced stage. Chronic kidney disease can be detected using blood and urine tests. The eGFR blood test measures the efficiency with which the kidneys function. Ultrasound, CT scan, X-ray, and MRI imaging examinations are also used for chronic kidney disease diagnosis. Chronic Kidney Disease Epidemiology Segmentation DelveInsight estimates that there were approximately 16 million diagnosed prevalent cases of chronic kidney disease in the 7MM in 2022. As per our analysis, chronic kidney disease has been identified as a female-dominant disease, with more females suffering than males. In 2022, 52% of cases of CKD were of females, while 48% of cases were of males in the 7MM. The chronic kidney disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Chronic Kidney Disease Prevalent Cases Chronic Kidney Disease Diagnosed Prevalent Cases Chronic Kidney Disease Gender-specific Diagnosed Prevalent Cases Chronic Kidney Disease Age-specific Diagnosed Prevalent cases Chronic Kidney Disease Complication-specific Diagnosed Prevalent cases Chronic Kidney Disease Stage-specific Diagnosed Prevalent Cases Chronic Kidney Disease Etiology-specific Diagnosed Prevalent Cases Download the report to understand which factors are driving chronic kidney disease epidemiology trends @ Chronic Kidney Disease Epidemiological Insights Chronic Kidney Disease Treatment Market There are various types of drugs in the chronic kidney disease market. Although available medications cannot cure CKD, they can treat problems and halt future kidney damage. DelveInsight's chronic kidney disease market projection focuses on pharmacological therapy (including all presently utilized off-label medications) recommended for chronic kidney disease management and excludes revenue produced by devices and surgical procedures, including dialysis. The chronic kidney disease drugs market is classified for the study based on drug class, such as erythropoietin stimulating agents (ESA), angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers (ACE-I and ARBs), antidiabetics, secondary hyperparathyroidism treatment (SHPT), and urate-lowering therapies. There are also approved therapies for chronic kidney disease treatment, such as KERENDIA, INVOKANA, JYNARQUE, and FARXIGA. According to DelveInsight's analysis, antidiabetics and antihypertensives are the most widely utilized among the top prescribed pharmaceuticals. Given the health risks associated with renal dysfunction, DelveInsight analysts developed a comprehensive understanding of chronic kidney disease and its etiologies, defining the breadth of the therapeutic paradigm. The chronic kidney disease treatment market is classified into three segments: diabetic kidney disease (DKD), polycystic kidney disease (PKD), and hypertension induced kidney disease. To know more about chronic kidney disease treatment guidelines, visit @ Chronic Kidney Disease Management Chronic Kidney Disease Therapies and Key Companies Renal Autologous Cell Therapy (REACT): ProKidney Bardoxolone methyl: Reata Pharmaceuticals, Inc. Ziltivekimab: Novo Nordisk A/S Semaglutide: Novo Nordisk A/S JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly and Company KBP-5074: KBP Biosciences KT-301: Kibow Pharma CIN-107 (Baxdrostat): Cincor Pharma Zibotentan: AstraZeneca ALLN-346: Allena Pharmaceuticals DM199: DiaMedica Therapeutics Inc Sotagliflozin: Lexicon Pharmaceuticals/Sanofi Learn more about the FDA-approved drugs for chronic kidney disease @ Drugs for Chronic Kidney Disease Treatment Chronic Kidney Disease Market Dynamics The dynamics of the chronic kidney disease market are expected to change in the coming years. The emerging treatment pipeline is robustly humongous, attributing to novel MoAs. Moreover, the rising data on chronic kidney disease and its risk factors is expected to add significantly to the patient pool. Furthermore, the current therapy paradigm includes FARXIGA (SGLT2 inhibitor), which is utilized for diabetic and non-diabetic chronic kidney disease patients. In the US, FARXIGA had a market size of USD 111 million in 2021 and is anticipated to reach USD 559 million as its peak revenue. Top SGLT2 players have been competing for lucrative approvals in recent years. The chronic kidney disease market may see another approval with Empagliflozin from Boehringer Ingelheim Pharmaceuticals, Inc by 2023. Empagliflozin has achieved landmark results in chronic kidney disease studies and would be a contender to FARXIGA because the findings could pave the road for a catch-up approval. Farxiga's sales have increased considerably as the label has expanded, but Jardiance is not far behind. According to the model, the therapy will produce a chronic kidney disease market size of USD 9 million by its launch year (2023), and this chronic kidney disease market size is predicted to grow to USD 772 million by 2032. However, several factors may impede the growth of the chronic kidney disease market, such as the undiagnosed, unreported cases, and unawareness about the disease may also impact future chronic kidney disease market growth. On the contrary, there are significant factors that may contribute to the growth in the market, as chronic kidney disease is associated with major complications, including anemia, hyperparathyroidism, and metabolic acidosis. Moreover, there is a scope for branded pharmacologic treatment with good safety and efficacy data and broader range coverage like impulse control. Scope of the Chronic Kidney Disease Market Report Therapeutic Assessment: Chronic Kidney Disease current marketed and emerging therapies Chronic Kidney Disease Market Dynamics: Attribute Analysis of Emerging Chronic Kidney Disease Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's Views, Analyst's Views, Chronic Kidney Disease Market Access and Reimbursement Discover more about chronic kidney disease drugs in development @ Chronic Kidney Disease Clinical Trials Table of Contents Related Reports Chronic Kidney Disease Epidemiology Forecast Chronic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic kidney disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Chronic Kidney Disease Pipeline Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic kidney disease companies, including KBP Biosciences, Eli Lilly and Company, Novo Nordisk, Prokidney, Boryung Pharmaceutical, among others. Moderate and Severe Chronic Kidney Disease Market Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others. Moderate and Severe Chronic Kidney Disease Pipeline Moderate and Severe Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others. Anemia In Chronic Kidney Disease Market Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others. Anemia In Chronic Kidney Disease Pipeline Anemia In Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anemia in chronic kidney disease companies, including Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Drug Approval

100 Deals associated with Ziltivekimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	US	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	CN	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	JP	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	AR	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	AU	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	BR	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	BG	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	CA	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	CZ	Novo Nordisk A/S	25 Jun 2024
Acute myocardial infarction	Phase 3	DK	Novo Nordisk A/S	25 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03926117 (RESCUE, Pubmed) Manual	Phase 2	Inflammation \| Chronic Kidney Diseases C-reactive Protein Expression	261	Ziltivekimab 7.5 mg	insczkycgw(rlpfolpnxy) = zmubgmdrfw jsdxujwilz (mfebaqaozr )	Positive	01 Jan 2024
				Ziltivekimab 15 mg	insczkycgw(rlpfolpnxy) = ubeyxxgcxl jsdxujwilz (mfebaqaozr )
NCT03926117 (RESCUE \| RESCUE Trial, CTgov)	Phase 2	Inflammation \| Chronic Kidney Diseases	264	Ziltivekimab (Placebo)	dpzmgyqpfe(qixahyyrnj) = tnwsrmikac finvezdnpf (tapotzhiho, zacxqdmzim - fjpydjjfyq) View more	-	09 Aug 2023
				Ziltivekimab (Ziltivekimab 7.5 mg)	dpzmgyqpfe(qixahyyrnj) = zlqlueretq finvezdnpf (tapotzhiho, vikmcxqpdp - btzsexjlro) View more
NCT03926117 (RESCUE Trial, ASN2021)	Phase 2	Chronic Kidney Diseases serum hemoglobin \| iron homeostasis \| high-sensitivity C-reactive protein	-	Ziltivekimab 7.5 mg	erxpelbqkz(obgsfswjcf) = dfwnctsxta lhazkqkwzz (djhqnsioqd )	Positive	27 Oct 2021
				Ziltivekimab 15 mg	erxpelbqkz(obgsfswjcf) = vehiyyzxqj lhazkqkwzz (djhqnsioqd )
NCT02868229 (CTgov)	Phase 1/2	Anemia	61	Placebo (Placebo)	meswjnvhob(vaijqtpikd) = hnddwboldi akgzervobx (ytvvpiwwqu, zbkqkypivx - eibybijfyf) View more	-	30 Jul 2021
				COR-001 (COR-001)	zczbevhoph(kkolrxgtna) = ybciqscfoq moydeatuqb (chzvwglswk, ltteaxshoj - duljvndipg)
NCT03926117 (RESCUE, Pubmed \| Lancet)	Phase 2	Atherosclerosis	264	Placebo	ngoblucgcw(chaobdscqf) = jqjxqbmgtx aeaxasusnr (pebxsdlcav )	Positive	14 May 2021
ASN2019	Phase 1	Chronic Kidney Diseases	12	COR-001 5 mg	xknknqqava(ziavumlgbz) = ceqbbszcqt gqyooqprgg (rxryclimyv )	Positive	05 Nov 2019
				COR-001 15 mg	xknknqqava(ziavumlgbz) = omezxfwbgv gqyooqprgg (rxryclimyv )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis